RADNOSTIX, INC. (INIS) Stock Price
RADNOSTIX, INC. Price
Revenue has compounded at 5.8% per year over the past 19 years to 13.07 M USD. Earnings per share have declined at 76.3% per year over the last 4 years. RADNOSTIX, INC.'s net margin stands at -6.9%, up from -9.3% several years earlier.
RADNOSTIX, INC. stock price
RADNOSTIX, INC. business model & stock analysis
Frequently asked questions about RADNOSTIX, INC.
International Isotopes Inc operates as a provider of nuclear medicine products and services. The company offers a wide range of radioisotopes, including those used in medical imaging, diagnosis, and therapy. Its business model revolves around producing and supplying high-quality radiopharmaceuticals, radiological devices, and related services to the global healthcare industry. International Isotopes Inc also provides consulting services and specialized software to assist medical professionals in utilizing their products effectively. With a focus on continuous innovation and quality assurance, the company serves as a reliable partner in the advancement of nuclear medicine technologies and treatments.
International Isotopes Inc is primarily active in the industries of nuclear medicine, radiopharmaceuticals, and nuclear energy.
The main competitors of International Isotopes Inc in the market include companies such as Lantheus Holdings Inc, GE Healthcare, Cardinal Health, and Bracco Imaging.
International Isotopes Inc (INIS) is a renowned company focused on the production and sale of nuclear medicine products. Established in 1995, INIS has become a prominent player in the global market. The company excels in providing a wide range of products and services, including radiological and nuclear materials, cobalt teletherapy sources, and calibration and reference sources. INIS has built a solid reputation through its commitment to quality, safety, and reliability. With their state-of-the-art facilities and expertise, International Isotopes Inc continues to be a leading provider of innovative solutions in the nuclear medicine industry.
International Isotopes Inc has achieved several significant milestones in its history. One of the major achievements includes the completion of its technetium-99m production facility in 2017, which positioned the company as a reliable supplier of medical isotopes. Additionally, the company successfully obtained a Drug Master File from the U.S. Food and Drug Administration for its radiopharmaceutical product, Sodium Iodide I-131, a crucial step in expanding its product offerings. Furthermore, International Isotopes Inc has made notable advancements in its proprietary processes for recycling used nuclear fuel, contributing to the development of a more sustainable and environmentally friendly nuclear industry.
International Isotopes Inc is primarily present in the United States.
International Isotopes Inc is a company that values integrity, innovation, and excellence in providing reliable and high-quality isotopes for various industries. With a strong corporate philosophy, International Isotopes Inc is committed to meeting the specific needs of its customers by offering a diverse range of products and services. The company strives to maintain strong relationships with its clients by consistently delivering exceptional value and ensuring customer satisfaction. International Isotopes Inc remains dedicated to continuous improvement and growth, fostering a culture of collaboration and efficiency. Through their dedication to advancing technology and emphasizing ethical conduct, International Isotopes Inc has established itself as a trusted leader in the industry.
Converted at the current exchange rate, the RADNOSTIX, INC. share trades at 0.06 EUR (0.06 USD).
International Isotopes Inc is a company that specializes in the production and marketing of radioactive and nuclear products. They offer products and services for the preservation, security, and use of isotopes. The company has been active in the market since 1995 and is headquartered in Idaho Falls, USA.
The revenue cannot currently be calculated for RADNOSTIX, INC..
The profit cannot currently be calculated for RADNOSTIX, INC..
The P/E ratio cannot be calculated for RADNOSTIX, INC. at the moment.
The P/S cannot be calculated for RADNOSTIX, INC. currently.
The Eulerpool Quality Score for RADNOSTIX, INC. is 3/10.
The ISIN of RADNOSTIX, INC. is US45972C1027. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of RADNOSTIX, INC. is 914371. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of RADNOSTIX, INC. is INIS. The ticker symbol is used to trade RADNOSTIX, INC. shares on the stock exchange.
RADNOSTIX, INC. stock
RADNOSTIX, INC. Peer Group
RADNOSTIX, INC. Ticker
RADNOSTIX, INC. FIGI
All fundamentals and in-depth analysis of RADNOSTIX, INC.
Our stock analysis for RADNOSTIX, INC. stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of RADNOSTIX, INC.. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.